跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LAPELGA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
LAPELGA
Authorized
STANDARD
LAPELGA
Apotex Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a6be410d6aed4776
Company
Apotex Inc
Type
Standard
Approval Details
Approval Id
a6be410d6aed4776
Drug Approval Canada Name
LAPELGA
Product Name
LAPELGA
Status
Marketed
Status Date
2022-11-28
Original Market Date
2022-11-28
Din
02529343
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
20:16.00
Atc Original
L03AA13 PEGFILGRASTIM
Atc Name
l 03 aa 13
Aig Number
0149962001
Company Name
Apotex Inc
Company Address
150 Signet Drive, Toronto, Ontario, Canada, M9L 1T9
Company Detail Path
/organization/apotex-inc
Company Information
Pharmaceutical Company Name
Apotex Inc
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
150 Signet Dr
Active Ingredients
PEGFILGRASTIM
6 MG / 0.6 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a6be410d6aed4776
Type
Standard
Back to Health Canada Approvals